Thank you, Mr. Chair. The supplementary appropriations are rarely a subject of significant debate in the House because they are -- you know, they're required to address money that's already been spent. But I think given the uncertain times we're in, given that there's a push for fiscal sustainability and fiscal discipline especially so we have resources to invest in the right priorities, I think it's appropriate to kind of take a look -- a deep -- a more careful look at how money's being spent. And there's some -- everything in here is very important. I'll be clear on that. And no one would question things like Metis health benefits and chemotherapy drugs and things like that. But when you see the cost overruns of these things, they're significant, and you have to wonder is there a way we could have planned for this more prudently so these wouldn't be such -- you know, wouldn't be significant amounts of money, and also is there a way to apply more fiscal discipline to the management decisions around how some of these funds are being spent. And, you know, we shouldn't be the -- we shouldn't be in a situation where because, typically, we don't have many questions and it is almost like a rubber stamping exercise to approve supplementary estimates that you could just do whatever you need to and they're going to get approved anyway even if you go a bit over. So I think in this case in particular, I certainly will be having more questions as we go through the document. But until we have -- until we start to see some progress on balanced budgets, we do need to take a closer eye here.

My question for the Minister is what is the impact of this on the supplementary reserve that's established by the main estimates? Thank you.